Hologic (NASDAQ:HOLX) Issues Q1 Earnings Guidance

Hologic (NASDAQ:HOLX) updated its first quarter earnings guidance on Monday. The company provided earnings per share guidance of $1.00-1.03 for the period, compared to the consensus earnings per share estimate of $1.03. The company issued revenue guidance of $1.025-1.035 billion, compared to the consensus revenue estimate of $1.04 billion. Hologic also updated its FY 2025 guidance to 4.250-4.350 EPS.

Hologic Stock Down 5.1 %

Shares of HOLX traded down $4.30 during mid-day trading on Tuesday, hitting $79.42. The company’s stock had a trading volume of 1,207,731 shares, compared to its average volume of 1,580,737. The firm has a market capitalization of $18.45 billion, a price-to-earnings ratio of 27.10, a PEG ratio of 2.98 and a beta of 0.98. The company’s 50-day moving average is $81.06 and its 200-day moving average is $78.08. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51. Hologic has a 52-week low of $66.93 and a 52-week high of $84.67.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting the consensus estimate of $1.01. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The business had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. During the same period in the prior year, the firm posted $0.89 earnings per share. The company’s quarterly revenue was up 4.5% on a year-over-year basis. On average, equities research analysts forecast that Hologic will post 4.09 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

HOLX has been the subject of a number of research reports. JPMorgan Chase & Co. boosted their target price on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research report on Tuesday. Citigroup cut Hologic from a “buy” rating to a “neutral” rating and reduced their price target for the company from $95.00 to $85.00 in a research report on Tuesday, October 1st. Royal Bank of Canada upped their price objective on Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a research report on Tuesday. Stephens reaffirmed an “overweight” rating and set a $92.00 price objective on shares of Hologic in a research note on Tuesday, July 30th. Finally, Leerink Partners cut their price objective on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Five investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $88.00.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.